SCHEMBL30288286

SCHEMBL30288286

FC(F)(F)C(F)(F)c1cccc(NCC2CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.44
CRHR1 P34998 4/20 0.42
IDH1 O75874 2/20 0.40
LIPC P11150 1/20 0.39
LIPG Q9Y5X9 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
PIM1 P11309 1/20 0.39
CNR2 P34972 1/20 0.38
IDH2 P48735 2/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
CCKBR P32239 1/20 0.35
PRKCQ Q04759 1/20 0.35
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30288260 0.87 RXFP1 (0.54) RXFP1CRHR1IDH1LIPCLIPG
SCHEMBL30288233 0.85 RXFP1 (0.42) RXFP1CRHR1IDH1LIPCLIPG
SCHEMBL1241128 0.81 RXFP1 (0.61) RXFP1CRHR1LIPCLIPGPIM1
SCHEMBL30288262 0.81 RXFP1 (0.61) RXFP1CRHR1LIPCLIPGPIM1
SCHEMBL13439179 0.81 RXFP1 (0.49) RXFP1CRHR1LIPCLIPGPIM1
SCHEMBL11935445 0.81 RXFP1 (0.49) RXFP1CRHR1LIPCLIPGPIM1
SCHEMBL30288292 0.75 IDH1 (0.43) RXFP1CRHR1IDH1LIPCLIPG
SCHEMBL4369018 0.75 CRHR1 (0.52) CRHR1ALDH1A1GAA
SCHEMBL30288245 0.73 CNR2 (0.39) RXFP1CRHR1IDH1LIPCLIPG
SCHEMBL13438988 0.72 CRHR1 (0.48) RXFP1CRHR1LIPCLIPGCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230055237-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS FLATLEY DISCOVERY LAB, LLC 2023-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230055237-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, MPST, CRAT RXFP1 931/4885CRHR1 4608/4885IDH1 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.